Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/19 → 3/31/21 |
Funding
- Ridgeline Therapeutics: $91,014.00
SBIR: Dose-Ranging Safety and Efficacy Studies to Advance Novel Mechanism-of-Action Drug Candidates to Reverse Age-Related Muscle Degeneration
- Fry, Christopher (PI)